# Effectiveness of Dapagliflozin for Weight Loss

Study · id `cardio:ct-nct03968224` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03968224](<https://clinicaltrials.gov/study/NCT03968224>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03968224

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT03968224. Randomized; no masking; primary purpose treatment. Start 2018-08-04 (actual); primary completion 2024-07-31 (actual). Results posted on 2025-10-15.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT03968224, source copy `cardio:ctgov-nct03968224-2025-10-15`, retrieved 2026-10-26)
- Started: 2018-08-04 (actual) (ClinicalTrials.gov record NCT03968224, source copy `cardio:ctgov-nct03968224-2025-10-15`, retrieved 2026-10-26)
- Primary completion: 2024-07-31 (actual) (ClinicalTrials.gov record NCT03968224, source copy `cardio:ctgov-nct03968224-2025-10-15`, retrieved 2026-10-26)
- Completion: 2024-07-31 (actual) (ClinicalTrials.gov record NCT03968224, source copy `cardio:ctgov-nct03968224-2025-10-15`, retrieved 2026-10-26)
- Results first posted: 2025-10-15 (ClinicalTrials.gov record NCT03968224, source copy `cardio:ctgov-nct03968224-2025-10-15`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT03968224, source copy `cardio:ctgov-nct03968224-2025-10-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03968224-2025-10-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness of Dapagliflozin for Weight Loss
- Condition: PreDiabetes
- Condition: Obesity, Morbid
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Dapagliflozin/Metformin
- Intervention (Drug): Metformin
- Lead sponsor: Centro Medico Nacional Siglo XXI IMSS
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: b26c9255fe335ea01fdfa9eb802c28bb571be91a271d39f0062c4b7c8302742a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
